Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.
Identifieur interne : 000C11 ( Main/Exploration ); précédent : 000C10; suivant : 000C12Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.
Auteurs : Mohammad Rasheduzzaman [Corée du Sud] ; Ji-Hong Moon [Corée du Sud] ; Ju-Hee Lee [Corée du Sud] ; Uddin Md Nazim [Corée du Sud] ; Sang-Youel Park [Corée du Sud]Source :
- The international journal of biochemistry & cell biology [ 1878-5875 ] ; 2018.
Descripteurs français
- KwdFr :
- AMP-Activated Protein Kinases (métabolisme), Apoptose (), Autophagie (), Cellules A549, Espèces réactives de l'oxygène (métabolisme), Humains, Ligand TRAIL (métabolisme), Phosphorylation (), Récepteurs au TRAIL (métabolisme), Régulation positive (), Thérapie moléculaire ciblée, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (métabolisme), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- anatomopathologie : Tumeurs du poumon.
- métabolisme : AMP-Activated Protein Kinases, Espèces réactives de l'oxygène, Ligand TRAIL, Récepteurs au TRAIL, Tumeurs du poumon.
- traitement médicamenteux : Tumeurs du poumon.
- Apoptose, Autophagie, Cellules A549, Humains, Phosphorylation, Régulation positive, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- A549 Cells, AMP-Activated Protein Kinases (metabolism), Apoptosis (drug effects), Autophagy (drug effects), Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (metabolism), Lung Neoplasms (pathology), Molecular Targeted Therapy, Phosphorylation (drug effects), Reactive Oxygen Species (metabolism), Receptors, TNF-Related Apoptosis-Inducing Ligand (metabolism), TNF-Related Apoptosis-Inducing Ligand (metabolism), Telmisartan (pharmacology), Telmisartan (therapeutic use), Up-Regulation (drug effects).
- MESH :
- chemical , metabolism : AMP-Activated Protein Kinases, Reactive Oxygen Species, Receptors, TNF-Related Apoptosis-Inducing Ligand, TNF-Related Apoptosis-Inducing Ligand.
- drug effects : Apoptosis, Autophagy, Phosphorylation, Up-Regulation.
- drug therapy : Lung Neoplasms.
- metabolism : Lung Neoplasms.
- pathology : Lung Neoplasms.
- chemical , pharmacology : Telmisartan.
- chemical , therapeutic use : Telmisartan.
- A549 Cells, Humans, Molecular Targeted Therapy.
Abstract
Telmisartan broadly used for the treatment of hypertension that is also known for its anticancer properties. TRAIL has the potential to kill tumor cells with minimal toxicity in normal cells by binding to death receptors, DR4 and DR5. Unfortunately, these TRAIL-death receptors have failed as most human cancers are resistant to TRAIL-mediated apoptosis. In this study, we evaluated telmisartan as a novel TRAIL-DR5-targeting agent with the aim of rendering TRAIL-based cancer therapies more active. Herein, we demonstrated that telmisartan could sensitize TRAIL and enhance NSCLC tumor cell death. The molecular mechanism includes the blocking of AMPK phosphorylation causes inhibition of autophagy flux by telmisartan resulting in ROS generation leading to death receptor (DR5) upregulation and subsequent activation of the caspase cascade by TRAIL treatment. Furthermore, using chloroquine and siATG5 significantly enhances ROS production and application of the ROS scavenger N-acetyl-cysteine (NAC) rescues the cells undergoing apoptosis by abrogating the expression of DR5 and finally the caspase cascade. Additionally, NAC treatment also maintains autophagy flux and makes the cells unresponsive to TRAIL. In summary, telmisartan in combination with TRAIL exhibits enhanced cytotoxic capacity toward lung cancer cells, thereby providing the potential for effective and novel therapeutic approaches to treat lung cancer.
DOI: 10.1016/j.biocel.2018.06.006
PubMed: 29929000
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000102
- to stream PubMed, to step Curation: 000102
- to stream PubMed, to step Checkpoint: 000084
- to stream Ncbi, to step Merge: 000451
- to stream Ncbi, to step Curation: 000451
- to stream Ncbi, to step Checkpoint: 000451
- to stream Main, to step Merge: 000C11
- to stream Main, to step Curation: 000C11
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.</title><author><name sortKey="Rasheduzzaman, Mohammad" sort="Rasheduzzaman, Mohammad" uniqKey="Rasheduzzaman M" first="Mohammad" last="Rasheduzzaman">Mohammad Rasheduzzaman</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Moon, Ji Hong" sort="Moon, Ji Hong" uniqKey="Moon J" first="Ji-Hong" last="Moon">Ji-Hong Moon</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Ju Hee" sort="Lee, Ju Hee" uniqKey="Lee J" first="Ju-Hee" last="Lee">Ju-Hee Lee</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Nazim, Uddin Md" sort="Nazim, Uddin Md" uniqKey="Nazim U" first="Uddin Md" last="Nazim">Uddin Md Nazim</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Park, Sang Youel" sort="Park, Sang Youel" uniqKey="Park S" first="Sang-Youel" last="Park">Sang-Youel Park</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea. Electronic address: sypark@chonbuk.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29929000</idno><idno type="pmid">29929000</idno><idno type="doi">10.1016/j.biocel.2018.06.006</idno><idno type="wicri:Area/PubMed/Corpus">000102</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000102</idno><idno type="wicri:Area/PubMed/Curation">000102</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000102</idno><idno type="wicri:Area/PubMed/Checkpoint">000084</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000084</idno><idno type="wicri:Area/Ncbi/Merge">000451</idno><idno type="wicri:Area/Ncbi/Curation">000451</idno><idno type="wicri:Area/Ncbi/Checkpoint">000451</idno><idno type="wicri:Area/Main/Merge">000C11</idno><idno type="wicri:Area/Main/Curation">000C11</idno><idno type="wicri:Area/Main/Exploration">000C11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.</title><author><name sortKey="Rasheduzzaman, Mohammad" sort="Rasheduzzaman, Mohammad" uniqKey="Rasheduzzaman M" first="Mohammad" last="Rasheduzzaman">Mohammad Rasheduzzaman</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Moon, Ji Hong" sort="Moon, Ji Hong" uniqKey="Moon J" first="Ji-Hong" last="Moon">Ji-Hong Moon</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Ju Hee" sort="Lee, Ju Hee" uniqKey="Lee J" first="Ju-Hee" last="Lee">Ju-Hee Lee</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Nazim, Uddin Md" sort="Nazim, Uddin Md" uniqKey="Nazim U" first="Uddin Md" last="Nazim">Uddin Md Nazim</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author><author><name sortKey="Park, Sang Youel" sort="Park, Sang Youel" uniqKey="Park S" first="Sang-Youel" last="Park">Sang-Youel Park</name><affiliation wicri:level="1"><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea. Electronic address: sypark@chonbuk.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596</wicri:regionArea><wicri:noRegion>Jeonbuk 54596</wicri:noRegion></affiliation></author></analytic><series><title level="j">The international journal of biochemistry & cell biology</title><idno type="eISSN">1878-5875</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A549 Cells</term><term>AMP-Activated Protein Kinases (metabolism)</term><term>Apoptosis (drug effects)</term><term>Autophagy (drug effects)</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (metabolism)</term><term>Lung Neoplasms (pathology)</term><term>Molecular Targeted Therapy</term><term>Phosphorylation (drug effects)</term><term>Reactive Oxygen Species (metabolism)</term><term>Receptors, TNF-Related Apoptosis-Inducing Ligand (metabolism)</term><term>TNF-Related Apoptosis-Inducing Ligand (metabolism)</term><term>Telmisartan (pharmacology)</term><term>Telmisartan (therapeutic use)</term><term>Up-Regulation (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP-Activated Protein Kinases (métabolisme)</term><term>Apoptose ()</term><term>Autophagie ()</term><term>Cellules A549</term><term>Espèces réactives de l'oxygène (métabolisme)</term><term>Humains</term><term>Ligand TRAIL (métabolisme)</term><term>Phosphorylation ()</term><term>Récepteurs au TRAIL (métabolisme)</term><term>Régulation positive ()</term><term>Thérapie moléculaire ciblée</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (métabolisme)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>AMP-Activated Protein Kinases</term><term>Reactive Oxygen Species</term><term>Receptors, TNF-Related Apoptosis-Inducing Ligand</term><term>TNF-Related Apoptosis-Inducing Ligand</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Autophagy</term><term>Phosphorylation</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>AMP-Activated Protein Kinases</term><term>Espèces réactives de l'oxygène</term><term>Ligand TRAIL</term><term>Récepteurs au TRAIL</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Telmisartan</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Telmisartan</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>A549 Cells</term><term>Humans</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Apoptose</term><term>Autophagie</term><term>Cellules A549</term><term>Humains</term><term>Phosphorylation</term><term>Régulation positive</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Telmisartan broadly used for the treatment of hypertension that is also known for its anticancer properties. TRAIL has the potential to kill tumor cells with minimal toxicity in normal cells by binding to death receptors, DR4 and DR5. Unfortunately, these TRAIL-death receptors have failed as most human cancers are resistant to TRAIL-mediated apoptosis. In this study, we evaluated telmisartan as a novel TRAIL-DR5-targeting agent with the aim of rendering TRAIL-based cancer therapies more active. Herein, we demonstrated that telmisartan could sensitize TRAIL and enhance NSCLC tumor cell death. The molecular mechanism includes the blocking of AMPK phosphorylation causes inhibition of autophagy flux by telmisartan resulting in ROS generation leading to death receptor (DR5) upregulation and subsequent activation of the caspase cascade by TRAIL treatment. Furthermore, using chloroquine and siATG5 significantly enhances ROS production and application of the ROS scavenger N-acetyl-cysteine (NAC) rescues the cells undergoing apoptosis by abrogating the expression of DR5 and finally the caspase cascade. Additionally, NAC treatment also maintains autophagy flux and makes the cells unresponsive to TRAIL. In summary, telmisartan in combination with TRAIL exhibits enhanced cytotoxic capacity toward lung cancer cells, thereby providing the potential for effective and novel therapeutic approaches to treat lung cancer.</div></front></TEI><affiliations><list><country><li>Corée du Sud</li></country></list><tree><country name="Corée du Sud"><noRegion><name sortKey="Rasheduzzaman, Mohammad" sort="Rasheduzzaman, Mohammad" uniqKey="Rasheduzzaman M" first="Mohammad" last="Rasheduzzaman">Mohammad Rasheduzzaman</name></noRegion><name sortKey="Lee, Ju Hee" sort="Lee, Ju Hee" uniqKey="Lee J" first="Ju-Hee" last="Lee">Ju-Hee Lee</name><name sortKey="Moon, Ji Hong" sort="Moon, Ji Hong" uniqKey="Moon J" first="Ji-Hong" last="Moon">Ji-Hong Moon</name><name sortKey="Nazim, Uddin Md" sort="Nazim, Uddin Md" uniqKey="Nazim U" first="Uddin Md" last="Nazim">Uddin Md Nazim</name><name sortKey="Park, Sang Youel" sort="Park, Sang Youel" uniqKey="Park S" first="Sang-Youel" last="Park">Sang-Youel Park</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29929000
|texte= Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29929000" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |